Protara Therapeutics Shares Retrospective Analysis Of OK-432 In Rare Lymphatic Malformations

  • Protara Therapeutics Inc TARA announced the results of a retrospective analysis of OK-432, the originator compound for TARA-002, its investigational therapy in development for lymphatic malformations (LMs), rare, congenital malformations of lymphatic vessels. 
  • The results from the analysis showed that OK-432 was clinically successful and generally well-tolerated in the treatment of both macrocystic and mixed-cystic LMs.
  • The retrospective analysis included 246 patients from a Phase 2 randomized study and 275 patients from an open-label study. 
  • In October, the FDA signed off Protara's Phase 1 trial of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.
  • Approximately 69% of patients achieved clinical success in the immediate treatment group after six months, while only 7.5% of patients in the delayed treatment group showed spontaneous resolution.
  • 73.1% of patients in the open-label study achieved clinical success.
  • Patients were followed for up to three years post-treatment with no significant safety concerns.
  • Price Action: TARA shares are up 1.43% at $2.84 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!